Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Atossa Therapeutics ( (ATOS) ) is now available.
On February 20, 2026, Atossa Therapeutics entered into a new at-the-market offering agreement with Rodman & Renshaw LLC, allowing the company to issue and sell up to $50 million of its common stock through the agent on Nasdaq or other trading venues. Atossa plans to direct any proceeds toward advancing its clinical programs, funding working capital and general corporate activities, and potentially pursuing complementary strategic assets, while retaining full discretion to suspend or terminate the offering.
The company agreed to pay Rodman & Renshaw a commission of up to 3% of gross proceeds and to reimburse certain offering expenses, under customary indemnification and contractual terms. On February 19, 2026, Atossa simultaneously terminated its prior open market sale agreement with Jefferies LLC, incurring no penalties and having executed no stock sales under that earlier arrangement, effectively consolidating its at-the-market capital-raising efforts under the new deal.
The most recent analyst rating on (ATOS) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Atossa Therapeutics stock, see the ATOS Stock Forecast page.
Spark’s Take on ATOS Stock
According to Spark, TipRanks’ AI Analyst, ATOS is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and rising TTM cash burn) and a strongly bearish technical setup (price far below key moving averages with negative MACD). Positive FDA-related corporate milestones provide some support, but valuation is difficult to justify with negative earnings and no dividend.
To see Spark’s full report on ATOS stock, click here.
More about Atossa Therapeutics
Atossa Therapeutics, Inc. is a biopharmaceutical company focused on developing clinical-stage product candidates. The firm intends to use capital raised to fund clinical development, working capital needs and broader corporate purposes, as well as potential licensing, acquisition or investment opportunities that complement its existing pipeline.
Average Trading Volume: 139,926
Technical Sentiment Signal: Sell
Current Market Cap: $37.37M
For a thorough assessment of ATOS stock, go to TipRanks’ Stock Analysis page.